Vir Biotechnology, Inc. VIR Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -720.8%-21.6pp | -699.2%+2,554pp | -3,253.6%-61.9pp | -3,191.7%-92.0pp | -3,099.7%-2,308pp | |
| Net margin | -676%-37.1pp | -638.9%+2,325pp | -2,963.5%-67.6pp | -2,895.9%-127pp | -2,769%-2,066pp | |
| EBITDA margin | -703%-20.9pp | -682.1%+2,502pp | -3,184.4%-53.6pp | -3,130.8%-93.0pp | -3,037.8%-2,266pp | |
| Free cash flow margin | -686.5%-108pp | -578.5%+2,150pp | -2,728.5%-274pp | -2,454.6%-431pp | -2,023.6%-1,412pp | |
| Returns | ||||||
| Return on equity | -47.7%-2.0pp | -45.7%+3.3pp | -49.1%-2.8pp | -46.2%-1.6pp | -44.6%-6.5pp | |
| Return on assets | -37.9%-1.5pp | -36.5%+3.2pp | -39.7%-1.2pp | -38.4%-1.2pp | -37.2%-5.8pp | |
| Return on invested capital | -67.6%-5.8pp | -61.8%-1.0pp | -60.7%+0.7pp | -61.4%-4.2pp | -57.2%-7.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 7.1×+1.6× | 5.5×-1.7× | 7.3×+0.2× | 7×+0.2× | 6.8×-1.9× | |
| Quick ratio | 7.1×+1.6× | 5.5×-1.7× | 7.3×+0.2× | 7×+0.2× | 6.8×-1.9× | |
| Cash ratio | 3.8×+1.3× | 2.6×+0.2× | 2.4×-0.5× | 2.9×+0.2× | 2.7×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $5.52-0.2% | $5.52-3.6% | $5.73-16.3% | $6.84-9.9% | $7.59-10.1% | |
| Valuation | ||||||
| Market capitalization | $1.43B+70.7% | $838.92M+5.8% | $793.21M+8.9% | $728.51M-18.0% | $888.69M-12.1% | |
| Enterprise value | $1.24B+78.9% | $695.71M-2.6% | $714.13M+36.2% | $524.47M-15.0% | $616.79M-21.9% | |
| Price / sales | 21.9×+9.6× | 12.2×-34.8× | 47×+8.7× | 38.3×-4.3× | 42.6×+29.0× | |
| Price / book | 1.8×+0.7× | 1.1×+0.1× | 1×+0.2× | 0.8×-0.1× | 0.9×0.0× | |
| EV / sales | 19×+8.9× | 10.1×-32.2× | 42.4×+14.8× | 27.6×-2.0× | 29.6×+18.9× | |
| Free cash flow yield | -31.4%+15.9pp | -47.3%+10.7pp | -58%+6.0pp | -64%-16.5pp | -47.5%-2.6pp | |
| Earnings yield | -30.9%+21.3pp | -52.2%+10.8pp | -63%+12.5pp | -75.5%-10.5pp | -65%-13.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vir Biotechnology, Inc.'s profit margins?
- Vir Biotechnology, Inc. (VIR) runs a 96.1% gross margin and a -720.8% operating margin, with a -676.0% net margin.
- Where do Vir Biotechnology, Inc.'s ratios come from?
- Every ratio is computed from Vir Biotechnology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.